Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06038630 · ClinicalTrials.gov registry record · Phase 2
129Xe MRI Cardiopulmonary
A Phase 2 study of Anemia and Interstitial Lung Disease, sponsored by Bastiaan Driehuys.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
- 1
- Study location
NCT06038630 is a Phase 2 study of Anemia and Interstitial Lung Disease that is actively recruiting participants, run by Bastiaan Driehuys. The registered enrollment target is 125 participants, below the 426-participant average among 72 other Anemia trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06038630, a Phase 2 study of Anemia and Interstitial Lung Disease, is actively recruiting participants, sponsored by Bastiaan Driehuys.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.
Conditions Studied
Interventions
- DRUG Hyperpolarized Xe129
- OTHER Oxygen Administration
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2024-01-12 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06038630
The ClinicalTrials.gov registry entry for NCT06038630 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 426-participant average among 72 other Anemia trials with a reported enrollment target (71% lower). The listed sponsor is Bastiaan Driehuys, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Anemia appearing as the primary indexed condition, and to 2 interventions - of which Hyperpolarized Xe129 is the first listed.
NCT06038630 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06038630 about?
NCT06038630 is a clinical study titled "129Xe MRI Cardiopulmonary". The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.
What is the current status of trial NCT06038630?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2024-01-12. Estimated completion is 2028-06-30.
What conditions does trial NCT06038630 study?
This clinical trial studies the following conditions: Anemia, Interstitial Lung Disease, Dyspnea, Chronic Thromboembolic Pulmonary Hypertension, Acute Pulmonary Embolism.
What interventions are being tested in trial NCT06038630?
The interventions under investigation include: Hyperpolarized Xe129 (DRUG), Oxygen Administration (OTHER).
Who is sponsoring clinical trial NCT06038630?
This trial is sponsored by Bastiaan Driehuys, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06038630 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
Study of DISC-0974-201 in Participants With IBD and Anemia
RECRUITING · Phase 2
-
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
RECRUITING · Phase 2
-
Choline and Iron Deficiency
RECRUITING · Phase 2
-
Luspatercept for Clonal Cytopenias of Uncertain Significance
RECRUITING · Phase 2
-
Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.